Summit Therapeutics Inc. (SMMT) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001599298

P/B 7,166.32

P/E -1,495.00

P/S 0.00

Market Cap 1,377.82 Bn

ROIC (Qtr) -404.21

Div Yield % 0.00

Rev 1y % (Qtr) 0.00

Total Debt (Qtr) 5.43 Mn

Debt/Equity (Qtr) 0.03

About

Healthy cash reserves of 238.88M provide 87.82x coverage of short-term debt 2.72M, demonstrating strong liquidity position and minimal refinancing risk.
Strong tangible asset base of 259.73M provides 47.85x coverage of total debt 5.43M, indicating robust asset backing and low credit risk.
Operating cash flow of (269.67M) provides strong 1315.44x coverage of operating expenses (205000), showing operational efficiency.
Tangible assets of 259.73M provide robust 6.50x coverage of other current liabilities 39.96M, indicating strong asset backing.
Cash reserves of 238.88M provide robust 3.68x coverage of current liabilities 64.93M, indicating strong short-term solvency.

Operating cash flow of (269.67M) barely covers its investment activities of 394.33M, with a coverage ratio of -0.68, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
Investment activities of 394.33M provide weak support for R&D spending of 441.76M, which is 0.89x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
The company's operating cash flow of (269.67M) shows concerning coverage of stock compensation expenses of 631.66M, with a -0.43 ratio indicating potential earnings quality issues.
Free cash flow of (270.17M) provides weak coverage of capital expenditures of 507000, with a -532.88 ratio suggesting additional external financing needs for growth initiatives.
Operating earnings of (912.93M) show weak coverage of depreciation charges of 126000, with a -7245.48 ratio indicating high capital intensity and potential reinvestment needs.

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,377.82 Bn	-1,495.00	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	442.39 Bn	6,453.60	88.96	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	114.19 Bn	31.07	9.74	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	76.52 Bn	16.71	5.37	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	56.84 Bn	1,304.71	17.71	3.21 Bn
6	ARGX	Argenx Se	53.58 Bn	35.57	27,941.68	-
7	BNTC	Benitec Biopharma Inc.	44.65 Bn	-1,067.50	0.00	0.00 Bn
8	INSM	INSMED Inc	36.43 Bn	-30.77	81.49	0.74 Bn

Metric	Value	Industry
EV to Assets	5,154.60	12.31
EV to Cash from Ops.	-5,002.90	23.25
EV to Debt	248,546.10	738.44
EV to EBIT	-1,477.78	-9.16
EV to EBITDA	-1,442.92	6.95
EV to Free Cash Flow [EV/FCF]	-4,993.52	21.90
EV to Market Cap	1.00	65.67
EV to Revenue	0.00	227.32
Price to Book Value [P/B]	7,018.52	22.34
Price to Earnings [P/E]	-1,464.17	-11.77

Metric	Value	Industry
Dividend Coverage Ratio	0.00	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	-105.10	841.00

Metric	Value	Industry
Capex Growth (1y) %	-299.21	-27.13
Cash and Equivalents Growth (1y) %	153.86	734.65
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	-432.19	-46.93
EBITDA Growth (1y) %	-375.83	-1.68
EBIT Growth (1y) %	-432.19	-56.45
EBT Growth (1y) %	-368.59	-12.70
EPS Growth (1y) %	-500.00	-28.31
FCF Growth (1y) %	-139.05	-31.90
Gross Profit Growth (1y) %	0.00	226.84

Metric	Value	Industry
Asset Utilization Ratio	0.00	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	3.68	3.85
Current Ratio	3.80	7.27
Debt to Equity Ratio	0.03	0.40
Interest Cover Ratio	-105.10	841.00
Times Interest Earned	-105.10	841.00

Metric	Value	Industry	Percentile
EBITDA Margin %	0.00	-18,234.31
EBIT Margin %	0.00	-18,580.80
EBT Margin %	0.00	-19,488.74
Gross Margin %	0.00	-7.59
Net Profit Margin %	0.00	-19,439.22